FLC Capital Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

FLC Capital Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-321	Closed	-$203K	–	175
2021 Q4	$203K	Sell	321 -300	-48%	-$184K	0.06%	165
2021 Q3	$376K	Sell	621 -62	-9%	-$38.5K	0.11%	129
2021 Q2	$381K	Hold	683	–	–	0.11%	128
2021 Q1	$323K	Buy	+683	New	+$333K	0.1%	131

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FLC Capital Advisors's REGN Position: Q1 2022 in Review

FLC Capital Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q1 2022, closing a stake of 321 shares — an estimated $203K sold.

FLC Capital Advisors first reported a position in REGN in Q1 2021 and held it in 4 quarters. The position peaked at $381K in Q2 2021. 1,095 funds tracked by Wall St. Rank hold REGN as of Q1 2022.

FLC Capital Advisors reported no remaining Regeneron Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
FLC Capital Advisors sold 321 Regeneron Pharmaceuticals shares in Q1 2022, an estimated $203K.
FLC Capital Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2021 and held it in 4 quarters.
FLC Capital Advisors's Regeneron Pharmaceuticals position peaked at $381K in Q2 2021.
1,095 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2022.

Based on FLC Capital Advisors's 13F filing for Q1 2022, filed 25 Apr 2022.